Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 16/20 | 0.57 |
| ▸ | JAK1 | P23458 | 15/20 | 0.57 |
| ▸ | JAK2 | O60674 | 14/20 | 0.57 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2378559 | 0.91 | JAK1 (0.62) | JAK3JAK1JAK2TYK2SYK | |
| SCHEMBL12333199 | 0.90 | JAK3 (0.57) | JAK3JAK1JAK2SYKMAPK1 | |
| SCHEMBL2378807 | 0.89 | JAK3 (0.64) | JAK3JAK1JAK2TYK2SYK | |
| SCHEMBL2377964 | 0.88 | JAK1 (0.60) | JAK3JAK1JAK2TYK2MAPK1 | |
| SCHEMBL12333693 | 0.86 | JAK1 (0.61) | JAK3JAK1JAK2TYK2SYK | |
| SCHEMBL2377469 | 0.86 | JAK1 (0.61) | JAK3JAK1JAK2TYK2SYK | |
| SCHEMBL2377938 | 0.84 | JAK1 (0.72) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL2377070 | 0.81 | JAK3 (0.60) | JAK3JAK1JAK2TYK2SYK | |
| SCHEMBL2379145 | 0.81 | JAK3 (0.58) | JAK3JAK1JAK2TYK2SYK | |
| SCHEMBL2378986 | 0.80 | JAK1 (0.65) | JAK3JAK1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | claimed |
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, BTK | JAK3 13/4885JAK1 6/4885JAK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.